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Abstract
Objective
To assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the
phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled
phase III studies in relapsing multiple sclerosis (RMS).
Methods
Brain MRI activity was determined in the phase II trial at monthly intervals in patients with
RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a
(30 μg). Annualized relapse rate (ARR; over various epochs) and time to first relapse were
analyzed in the pooled population of the phase III OPERA (A Study of Ocrelizumab in
Comparison With Interferon Beta-1a [Rebif] in Participants With Relapsing Multiple Scle-
rosis) I and OPERA II trials in patients with RMS receiving ocrelizumab (600 mg) or sub-
cutaneous IFN-β-1a (44 μg).
Results
In patients with RRMS, ocrelizumab reduced the number of new T1 gadolinium-enhancing
lesions by week 4 vs placebo (p = 0.042) and by week 8 vs intramuscular IFN-β-1a (p < 0.001).
Ocrelizumab also reduced the number of new or enlarging T2 lesions appearing between weeks
4 and 8 vs both placebo and IFN-β-1a (both p < 0.001). In patients with RMS, ocrelizumab
significantly reduced ARR (p = 0.005) and the probability of time to first protocol-defined
relapse (p = 0.014) vs subcutaneous IFN-β-1a within the first 8 weeks.
Conclusion
Epoch analysis of MRI-measured lesion activity in the phase II study and relapse rate in the
phase III studies consistently revealed a rapid suppression of acute MRI and clinical disease
activity following treatment initiation with ocrelizumab in patients with RRMS and RMS,
respectively.
Classification of evidence
This study provides Class II evidence that for patients with RRMS and RMS, ocrelizumab
suppressed MRI activity within 4 weeks and clinical disease activity within 8 weeks.
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In multiple sclerosis (MS), a rapid onset of action in controlling
clinical andMRI disease activity is an important therapeutic goal
tominimize neurologic damage and irreversible accumulation of
disability.1–3 Pivotal studies of disease-modifying treatments
(DMTs) in patients with relapsing-remitting MS (RRMS) have
generally shown reductions in the annualized relapse rate
(ARR) vs placebo or active comparator treatment over 1–2
years,4–19 although more recent studies, including post hoc
analyses, have demonstrated benefits as early as 12 weeks after
DMT initiation.1–3 However, the trial design and frequency of
assessments often limit the study of onset of action, which
particularly applies to MRI outcomes.2,20–22 In the 2 identical
phase III trials, OPERA (A Study of Ocrelizumab in Com-
parison With Interferon Beta-1a [Rebif] in Participants With
Relapsing Multiple Sclerosis) I and OPERA II, in patients with
relapsing MS (RMS), ocrelizumab reduced ARR assessed at 96
weeks (primary outcome), compared with interferon (IFN)–β-
1a. In addition, reductions in MRI disease activity were ob-
served as early as week 24, commensurate with the first MRI
assessment.23 In the phase II clinical trial of ocrelizumab in
patients with RRMS, where MRI assessments were scheduled
every 4 weeks for the first 6 months, reductions in MRI lesion
measures were evident between 12 and 24 weeks.24
A rapid onset of ocrelizumab effect was observed on B-cell
numbers, with near-complete depletion of B cells in the pe-
ripheral blood by day 4, although potentially this could occur
within hours.25 The objective of the current study was to
reanalyze ARR data from the pooled phase III OPERA I and
OPERA II studies and MRI data from the phase II study at
earlier time points than reported thus far.
Methods
Trial design and patients
New focal brain MRI activity (new T1 gadolinium
[Gd]-enhancing lesions and new or enlarging T2 lesions)
was determined in the phase II study (NCT00676715).
This was a multicenter, randomized, parallel-group, par-
tially blinded, placebo and IM IFN-β-1a–controlled dose-
finding study of ocrelizumab in patients with RRMS.
Baseline demographics and disease characteristics were bal-
anced across study arms. Study details have been reported
previously (figure e-1, doi.org/10.5061/dryad.3jd86nj).24 Key
eligibility criteria included age 18–55 years, diagnosis of RRMS
(2005 revisedMcDonald criteria),26 and an ExpandedDisability
Status Scale (EDSS) score of 1–6 at baseline. Patients were
randomized (1:1:1:1) to receive placebo or low-dose (600 mg)
or high-dose (2,000 mg) ocrelizumab in 2 doses on days 1 and
15, or IM IFN-β-1a (30 μg) once a week (figure e-1, doi.org/10.
5061/dryad.3jd86nj), with 4-weekly MRI scans performed for
the first 6 months.24 In this study, analysis of brain MRI activity
was conducted using the intent-to-treat (ITT) population, only
in patients receiving 600 mg ocrelizumab (the current approved
dose), to be comparable with the phase III trials in RMS.
ARR was determined in the pooled population of the identical
phase III, multicenter, randomized, double-blind, double-
dummy, SC IFN-β-1a–controlled trials of ocrelizumab in
patients with RMS (OPERA I [NCT01247324] and OPERA
II [NCT01412333]).23 Baseline demographics and disease
characteristics were comparable across treatment arms within
each study, and between studies. Study details have been
reported previously (figure e-2, doi.org/10.5061/dryad.
3jd86nj).23 Key eligibility criteria included age 18–55 years,
diagnosis of relapsing MS (2010 revised McDonald crite-
ria),27 and an EDSS score of 0–5.5 at screening. Consistency
of baseline characteristics and treatment effects across both
OPERA studies met predetermined criteria for pooled effi-
cacy analysis, including ARR.23 Patients were randomized (1:
1) to receive either 600 mg ocrelizumab by IV infusion every
24 weeks or SC IFN-β-1a 3 times per week at a dose of 44 μg
throughout the 96-week treatment period. Relapse in-
formation was collected continuously through scheduled
neurologic examinations, and any unscheduled visit triggered
by the patient or through structured telephone interviews
conducted every 4 weeks from week 8 to identify any new or
worsening neurologic symptoms (figure e-2, doi.org/10.
5061/dryad.3jd86nj).23
Standard protocol approvals, registrations,
and patient consents
The relevant institutional review boards/ethics committees
approved the protocols (ClinicalTrials.gov identifier numbers
NCT00676715, NCT01247324, and NCT01412333). All
patients provided written informed consent.
Classification of evidence
This study provides Class II evidence that for patients with
RRMS and RMS, ocrelizumab suppressedMRI activity within
4 weeks and clinical disease activity within 8 weeks.
Laboratory assessments
CD19 count is a sensitive but nonspecific pharmacodynamic
marker for anti-CD20 efficacy. In the OPERA I andOPERA II
Glossary
ARR = annualized relapse rate; BBB = blood–brain barrier; CI = confidence interval; DMT = disease-modifying treatment;
EDSS = Expanded Disability Status Scale; FS = Functional System; Gd = gadolinium; HR = hazard ratio; IFN = interferon;
ITT = intent to treat; MS = multiple sclerosis; OPERA = A Study of Ocrelizumab in Comparison with Interferon Beta-1a
[Rebif] in Participants with Relapsing Multiple Sclerosis; RMS = relapsing multiple sclerosis; ROW = rest of world; RRMS =
relapsing-remitting multiple sclerosis.
Neurology.org/N Neurology | Volume 93, Number 19 | November 5, 2019 e1779
trials, anti-CD19 was used to measure CD20-positive cells as
ocrelizumab would interfere with an anti-CD20 assay.
Clinical and MRI endpoints
The primary endpoint of the OPERA I and OPERA II trials
was ARR at 96 weeks, which reflects the number of relapses
meeting the prespecified criteria observed per person-year of
follow-up. The probability of first protocol-defined relapse was
also determined. Protocol-defined relapses were defined as
new or worsening neurologic symptoms attributable to MS
that persisted for over 24 hours, were immediately preceded by
a stable or improving neurologic state for at least 30 days, and
were accompanied by objective neurologic worsening consis-
tent with an increase of at least half a step on the EDSS scale, 2
points on at least one of the appropriate Functional System
(FS) scale scores, or one point on 2 or more FS scale scores.23
In the phase II study, brainMRI was performed at baseline and
weeks 4, 8, 12, 16, 20, and 24 during the core placebo-
controlled period and at the end of the dose-blinded extension
at week 96 in the ocrelizumab arm only; newT1Gd-enhancing
lesions or new or enlargingT2 lesions on any postbaseline scan
were considered evidence of MRI disease activity.
Statistical analyses
In the ITT population in the phase II study, acuteMRI disease
activity data were reanalyzed up to week 12 by 4-weekly
epochs. The number of new T1 Gd-enhancing lesions (at
weeks 4, 8, and 12) and the number of new or enlarging T2
lesions, regardless of enhancement status (during weeks 0–4,
4–8, and 8–12), were compared in patients treated with
600 mg ocrelizumab and those receiving placebo or IM IFN-
β-1a using a negative binomial model adjusted for baseline
lesion status (present vs absent in T1 Gd-enhancing lesions
for T1 model; total T2 lesion volume for T2 model), baseline
EDSS score (≤2.5 vs >2.5), and geographic region (US vs rest
of world [ROW]). The phase II MRI data were originally
analyzed using the van Elteren test, stratified by geographic
region and presence of baseline Gd-enhancing lesions (absent
or present)24; however, the negative binomial model was
adopted here, consistent with the MRI analyses in the phase
III OPERA I and OPERA II studies.23 The negative binomial
model was adjusted for baseline EDSS score and geographic
region as there is an underlying assumption that these pre-
defined subgroups of patients may behave differently.
Based on the ITT population over the controlled treatment
phase (baseline to 96 weeks) from the pooled OPERA I and
OPERA II data, post hoc exploratory analyses evaluated the
effect of ocrelizumab compared with SC IFN-β-1a on ARR for
several epochs, including weeks 0–8, 0–12, 0–24, and 0–48. For
each epoch, the adjusted ARR, rate ratio (ocrelizumab over SC
IFN-β-1a) and its 95% confidence interval (CI), and the p value
were derived from the Poisson model adjusting for study
(OPERA I vs OPERA II), region (US vs ROW), and baseline
EDSS score (<4.0 vs≥4.0). The log-transformed exposure time
in years was included as an offset variable for appropriate
computation of relapse rate. The probability of time to first
protocol-defined relapse at weeks 8, 16, 24, 48, 72, and 96 was
estimated using the Kaplan-Meier method and Greenwood
formula. The hazard ratios (HRs) (ocrelizumab vs SC IFN-
β-1a) and 95% CIs were based on a Cox proportional hazards
model, adjusting for study (OPERA I vs OPERA II), region
(US vs ROW), and baseline EDSS score (<4.0 vs ≥4.0). p
Values were not adjusted for multiple comparisons.
Data availability
Qualified researchers may request access to individual patient-
level data through the clinical study data request platform
(clinicalstudydatarequest.com). Further details on Roche cri-
teria for eligible studies are available here (clinicalstudydatare-
quest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For
further details on the Roche Global Policy on the Sharing of
Clinical Information and how to request access to related
clinical study documents, see roche.com/research_and_de-
velopment/who_we_are_how_we_work/clinical_trials/our_
commitment_to_data_sharing.htm.
Results
Patient demographics and
disease characteristics
In the phase II trial, the population analyzed included 163
patients treated with placebo, n = 54; 30 μg IM IFN-β-1a, n =
54; or 600mg ocrelizumab, n = 55 (the ocrelizumab high dose
was not included in this analysis). In the OPERA I and OP-
ERA II trials, the pooled population comprised 1,656 patients
(44 μg SC IFN-β-1a, n = 829; ocrelizumab, n = 827). Baseline
demographics and disease characteristics were similar within
each study arm and between studies for the phase II and
pooled phase III patient populations, although mean EDSS
was higher and there were fewer treatment-naive patients in
the phase II study compared with the pooled phase III study
population (table).
Changes in B-cell numbers on ocrelizumab
treatment initiation
CD19+ cells represent a measure of B-cell counts in anti-
CD20–treated patients. In the pooled OPERA I and OPERA
II population, the level of CD19+ cells decreased to negligible
levels with ocrelizumab treatment by week 2 (figure e-3, doi.
org/10.5061/dryad.3jd86nj).
New focal brain MRI activity in the phase
II study
MRI lesion activity was determined in the phase II study up to
week 12 by 4-weekly epochs, comparing patients treated with
ocrelizumab 600 mg with those receiving placebo or IM IFN-
β-1a. In the primary analysis of the phase II study, ocrelizumab
600 mg reduced the cumulative number of T1 Gd-enhancing
lesions observed between weeks 12 and 24 by 89% (95% CI
68%–97%) compared with placebo (p < 0.001).24 The total
number of new or enlarging T2 lesions at week 24 was re-
duced with ocrelizumab 600 mg (mean [SD] 0.0 [0.1])
compared with placebo (p < 0.001).24 By performing an
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epoch analysis of lesion activity by 4-weekly intervals from
baseline to week 12, we found that ocrelizumab significantly
reduced the number of new T1Gd-enhancing lesions by week
4 vs placebo (adjusted mean: placebo 0.839, ocrelizumab
600 mg 0.319, p = 0.042) and by week 8 vs IM IFN-β-1a
(adjusted mean: IM IFN-β-1a 1.276, ocrelizumab 600 mg
0.041, p < 0.001) (figure 1). Ocrelizumab also significantly
reduced the number of new or enlarging T2 lesions appearing
between weeks 4 and 8 vs placebo (adjusted mean: placebo
1.205, ocrelizumab 600 mg 0.056, p < 0.001) and IM IFN-
β-1a (adjusted mean: IM IFN-β-1a 0.968, ocrelizumab
600 mg 0.056, p < 0.001), but not between weeks 0 and 4
(figure 2). Furthermore, separately, the number of new T2
lesions (figure e-4, doi.org/10.5061/dryad.3jd86nj) and the
number of newly enlarging T2 lesions (figure e-5, doi.org/10.
5061/dryad.3jd86nj) appearing between weeks 4 and 8 were
significantly reduced with ocrelizumab vs placebo and IM
IFN-β-1a. In addition, the proportion of patients free of T1
Gd-enhancing lesions at each measured epoch from week 4 to
week 12 in 4-weekly intervals was higher with ocrelizumab vs
placebo and IM IFN-β-1a (figure 3). Analysis of MRI lesion
measures to week 24 was also performed and results were
consistent with week 12 (data not shown). Consistent results
in brain MRI activity were also observed with ocrelizumab
2,000 mg (data not shown).
Clinical activity in the phase III OPERA I and
OPERA II studies
In the pooled analyses of the OPERA I and OPERA II trials,
ocrelizumab significantly reduced ARR, the primary outcome in
the OPERA studies, by 46.5% (p < 0.001) over 96 weeks
compared with SC IFN-β-1a (figure 4). This favorable outcome
onARRwas seenwith ocrelizumab comparedwith SC IFN-β-1a,
at the various epochs studied: ocrelizumab significantly reduced
ARR within the first 8 weeks (54.9%, p = 0.005), 12 weeks
(48.8%, p = 0.002), 24 weeks (40.4%, p < 0.001), and 48 weeks
(48.7%, p < 0.001) (figure 4). ARRwas consistent for treatment-
naive patients, as per theOPERAdefinition, andDMTswitchers.
However, this is a small cohort only, mostly consisting of patients
previously treated with IFN and glatiramer acetate, therefore
underpowered to detect differences between groups.
In addition, analysis of time to first onset of protocol-defined
relapse demonstrated a lower relative risk of experiencing
a relapse with ocrelizumab by week 8 (SC IFN-β-1a 0.04 [95%
CI 0.03–0.05], ocrelizumab 0.02 [95% CI 0.01–0.03], p =
Table Baseline demographics and disease characteristics for phase II and pooled OPERA I and OPERA II populations
Baseline demographics and
disease characteristics
Phase II Pooled OPERA I and OPERA II
Placebo
(n = 54)
IM IFN-β-1a,
30 μg (n = 54)
Ocrelizumab,
600 mg (n = 55)
SC IFN-β-1a,
44 μg (n = 829)
Ocrelizumab,
600 mg (n = 827)
Age, y, mean (SD) 38.0 (8.8) 38.1 (9.3) 35.6 (8.5) 37.2 (9.2) 37.1 (9.2)
Female, n (%) 36 (66.7) 32 (59.3) 35 (63.6) 552 (66.6) 541 (65.4)
Time since MS symptom onset, y
Mean (SD) 7.2 (6.1) 8.4 (7.2) 6.9 (5.0) 6.5 (6.1) 6.7 (6.2)
Median (range) 4.8 (0.6–26.2) 5.3 (0.8–35.2) 6.5 (0.5–20.5) 4.8 (0.2–34.9) 5.1 (0.2–33.9)
Time since MS diagnosis, y
Mean (SD) 3.9 (4.6) 5.1 (5.2) 4.7 (4.1) 3.9 (4.9) 4.0 (4.9)
Median (range) 2.7 (0.1–19.2) 3.3 (0.1–20.2) 3.6 (0.1–16.5) 1.7 (0.1–28.5) 1.8 (0.0–28.9)
MS disease-modifying treatment-naive, n (%)a 38 (70.4) 31 (57.4) 30 (54.5) 606 (73.4)b,c 605 (73.3)b,d
EDSS
Mean (SD) 3.2 (1.4) 3.1 (1.5) 3.5 (1.5) 2.8 (1.3)e 2.8 (1.3)
Median (range) 3.0 (1.0–6.0) 3.0 (1.0–6.0) 3.5 (1.0–6.0) 2.5 (0.0–6.0)e 2.5 (0.0–6.0)
MRI
Patients with T1 Gd-enhancing lesions, n (%) 21 (44.7)f 17 (34.0)g 26 (51.0)h 327 (39.8)i 333 (40.7)j
Brain T2 hyperintense lesion volume, cm3
Mean (SD) 9.0 (9.8)f 13.2 (17.2)k 14.0 (19.9)h 10.2 (11.8)l 10.8 (14.1)i
Median (range) 4.8 (0.0–39.9)f 8.2 (0.0–102.9)k 6.7 (0.0–93.8)h 6.2 (0.0–76.1)l 5.4 (0.0–96.0)i
Abbreviations: EDSS = Expanded Disability Status Scale; Gd = gadolinium; IFN = interferon; MS = multiple sclerosis.
a Only data from 2 years prior to study entry are collected and analyzed.
b Data include patients who were untreated with any disease-modifying therapy in the 2 years before screening.
c n = 826; d n = 825; e n = 828; f n = 47; g n = 50; h n = 51; i n = 822; j n = 818; k n = 49; l n = 824.
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0.014) (figure 5), and over all subsequent intervals (week 16,
24, 48, 72, and 96; all p < 0.002). The cumulative probability
of first protocol-defined relapse at 96 weeks was 0.32 (95% CI
0.28–0.35) for SC IFN-β-1a and 0.19 (95% CI 0.16–0.21) for
ocrelizumab (p < 0.001) (figure 5). Treatment with ocreli-
zumab led to a 46% risk reduction in time to first protocol-
defined relapse over 96 weeks compared with SC IFN-β-1a
(HR 0.54 [95% CI 0.44–0.66], p < 0.001).
Discussion
This post hoc analysis of phase II and pooled phase III studies
demonstrated that ocrelizumab has a rapid onset of activity as
early as 4 weeks. Epoch analysis of MRI-measured new focal
lesion activity in the phase II study and relapse rate in the
phase III studies consistently disclosed a rapid suppression of
acute MRI and clinical disease activity following treatment
initiation, respectively. In the 2 OPERA studies in patients
with RMS, ocrelizumab was associated with a significant re-
duction in relapse rate and the cumulative probability of first
protocol-defined relapse over time, as early as 8 weeks after
treatment initiation, suggesting a rapid onset of clinical effi-
cacy. The rapid onset of the effect of ocrelizumab on acute
clinical disease activity in the phase III trials corresponds
temporally with the observed effect on acute new focal MRI
disease activity in the phase II analysis. Ocrelizumab 600 mg
demonstrated rapid suppression of new focal brain MRI ac-
tivity vs placebo as early as week 4, and near-complete by week
Figure 1 The number of new T1 gadolinium (Gd)-enhancing lesions in the phase II population
Intention-to-treat population. Interferon (IFN)–β-1a was administered as a 30 μg IM injection once a week. aNegative binomial model adjusted for baseline T1
Gd-enhancing lesions (present vs absent), baseline Expanded Disability Status Scale (EDSS) score (≤2.5 vs >2.5), and geographic region (US vs rest of world).
b Error bars are 95% confidence intervals.
Figure 2 The number of new or enlarging T2 lesions in the phase II population
Intention-to-treat population. Interferon (IFN)–β-1a was administered as a 30 μg IM injection once a week. aEnlarging T2 lesions were newly enlarging.
bNegative binomialmodel adjusted for baseline T2 lesion volume, baseline ExpandedDisability Status Scale (EDSS) score (≤2.5 vs >2.5), and geographic region
(US vs rest of world). cError bars are 95% confidence intervals.
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8. Post hoc analyses of clinical study data have shown
reductions in ARR within the first 12 weeks vs placebo for
natalizumab, fingolimod, and dimethyl fumarate.1–3 Con-
versely, the early benefits on MRI measures after DMT ini-
tiation seen at 1, 3, and 6 months for natalizumab, dimethyl
fumarate, and fingolimod vs placebo were dependent on the
first available MRI scheduled assessments.2,20–22 Similarly, in
the ocrelizumab pivotal studies in RMS, most of the new or
enlarging T2 lesions in the ocrelizumab groups occurred be-
tween baseline and week 24 (first scheduled scan), perhaps
reflecting residual new T2 lesion formation carried over
within the first weeks of treatment initiation,28 and near-
complete suppression of T1 Gd-enhancing lesions at week 24.
The current analysis of phase II MRI data of the ocrelizumab
600 mg dose, with increased scan frequency, reveals the
suppression of new focal brain MRI lesion activity was in fact
near-complete by week 8. As early treatment initiation can
minimize neurologic damage and disability worsening in
patients with MS, and is associated with improved clinical
outcomes, the available data from this study and the pivotal
trials suggest ocrelizumab could provide both early and long-
term benefits in patients with MS.
The fast B-cell depletion in the peripheral blood may, in part,
explain the rapid efficacy of ocrelizumab. These findings are
consistent with previous observations and the known
Figure 3 The proportion of patients free of T1 gadolinium (Gd)-enhancing lesions in the phase II population
Intention-to-treat population. Interferon (IFN)–β-1a was administered as a 30 μg IM injection once a week. Proportion of patients free of T1 Gd-enhancing
lesions at week 24: placebo 74.5%; IFN-β-1a 30 μg 61.4%; ocrelizumab 600mg 100%. a For the calculation of total number of new Gd-enhancing T1 lesions on
MRI scans of the brain at a specific week and before week 24, the missing value at a time point is not going to be imputed.
Figure 4 The adjusted annualized relapse rate (ARR) in the pooled OPERA intention-to-treat (ITT) population
Intention-to-treat population. Interferon (IFN)–β-1a was administered as an SC infusion 3 times per week at a dose of 44 μg. a Adjusted by study, baseline
Expanded Disability Status Scale (EDSS) score (<4.0 vs ≥4.0), and geographic region (US vs rest of world) using Poisson model. b Compared with IFN-β-1a.
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pharmacodynamic effects of ocrelizumab, which were asso-
ciated with systemic depletion of B cells to negligible levels
within 4 days (first available assessment in humans) or po-
tentially earlier.25,29 This may in turn lead to downregulation
of circulating T cells and their entrance into the CNS.30 The
explanation of the rapid onset of efficacy on T1 Gd-enhancing
lesions with ocrelizumab will require a better understanding
of the contributing factors to the integrity of the blood–brain
barrier (BBB) and what role B cells and their depletion play in
the interaction with T cells and possibly myeloid/glial cells.
Initial studies in a limited number of patients with MS suggest
that anti-CD20 therapies (rituximab and ocrelizumab) mod-
ulate (B-cell–derived) circulating cytokine levels, which may
influence BBB permeability.
Limitations exist in the data presented. As the analyses were
post hoc, no adjustment for multiplicity was made; however,
all results are in the same direction and reveal, as expected,
a further increasing treatment effect over time. It should be
noted that the p values reported should be interpreted with
a certain degree of caution. Despite most baseline demo-
graphics and disease characteristics being similar between
studies for the phase II and pooled OPERA I and OPERA II
patient populations, there were some differences between
these 2 populations for EDSS and MS disease-modifying
treatment-naive participants. In addition, the populations
were different between the phase II study (patients with
RRMS) and the pooled OPERA I and OPERA II studies
(patients with RMS). With this and other clinical studies, the
assessment time points defined in the study protocol limit the
study of the onset of a measurable treatment effect on out-
comes (here B-cell depletion, MRI activity, and clinical ac-
tivity). The rapid onset of action of ocrelizumab was assessed
using an active drug (SC IFN-β-1a), which should be con-
sidered when comparing the time to effect with other DMTs
in studies which were placebo controlled.1–3 Although the
treating physician does not conduct the assessment for ARR,
IFN-β-1a flu-like side effects can potentially unblind patients
and affect their initiation of relapse evaluation.
Although benefit/risk was not analyzed in DMT switchers in
this study, the rapid onset of the ocrelizumab effect may have
implications for patients switching from other therapies.
Patients and clinicians are concerned that delayed onset of
therapeutic effect, either with new treatments or after
switching, can put patients at risk of new relapses and lead to
an increase in disability. Treatment onset of ocrelizumab on
ARR was found to be consistent with treatment-naive patients
for IFN and glatiramer acetate switchers; numbers for patients
switching from other DMTs were too low for meaningful
analyses. Rapid control of subclinical disease activity is an
important treatment goal to minimize disease activity and
potentially associated axonal damage that may ultimately lead
to disability progression in MS.31 This should be balanced
against potential safety concerns when switching between
drugs that may have additive pharmacodynamic effects.
Patients with RRMS with a suboptimal response to previous
DMTs switching to ocrelizumab are being studied in 2 on-
going phase IIIb MS trials (CHORDS [NCT02637856] and
CASTING [NCT02861014]).
Overall, ocrelizumab consistently demonstrated a rapid onset
of efficacy on both clinical and MRI measures of acute disease
activity, as early as 4 weeks, in the phase II and pooled phase
III OPERA I and OPERA II trials. Future analyses, including
post hoc exploratory analyses using data from the open-label
Figure 5 The probability of first protocol-defined relapse in the pooled OPERA intention-to-treat (ITT) population
Intention-to-treat population. Interferon (IFN)–β-1a was administered as an SC infusion 3 times per week at a dose of 44 μg. Probability of relapse estimates
(95% confidence interval [CI]) at weeks 8, 16, 24, 48, 72, and 96 were calculated using Kaplan-Meier and Greenwood formula. p Values not adjusted for
multiplicity of testing. HR = hazard ratio.
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extension study, should help to identify if patients who switch
from IFN-β-1a to ocrelizumab demonstrate a similar rapid
suppression of clinical and MRI disease activity, and whether
the early effects of ocrelizumab translate into long-term
benefit in patients continuing ocrelizumab treatment.
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